Henning T. Mouridsen

Biochemistry, Genetics and Molecular Biology · Life Sciences

66h-index20.6kcitations305works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(135), Estrogen and related hormone effects(77), Cancer Treatment and Pharmacology(63), HER2/EGFR in Cancer Research(48), Sarcoma Diagnosis and Treatment(32)

Publications305 total

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
The Lancet·2023· 169 citedOpen Access
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
npj Breast Cancer·2020· 27 citedOpen Access
Is DBCG abreast of new developments?
Acta Oncologica·2018· 18 citedOpen Access
Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration
Acta Oncologica·2017· 24 citedOpen Access
The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016
Acta Oncologica·2017· 71 citedOpen Access
Provision of data from the clinical database and of biological material from the tumor bank of the Danish Breast Cancer Cooperative Group 2008–2017
Acta Oncologica·2017· 2 citedOpen Access
The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study
Acta Oncologica·2017· 4 citedOpen Access
Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial
Acta Oncologica·2017· 4 citedOpen Access
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
Breast Cancer Research and Treatment·2017· 12 citedOpen Access
Heavy international support to the Danish mammography screening programme
2017
Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early<i>TOP2A</i>-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial
Journal of Clinical Oncology·2017· 65 cited
Danish Breast Cancer Cooperative Group
Clinical Epidemiology·2016· 150 citedOpen Access
Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment
Acta Oncologica·2016· 45 citedOpen Access
DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer
University of Southern Denmark Research Portal (University of Southern Denmark)·2016
Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer
Acta Oncologica·2013· 37 citedOpen Access
One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer
European Journal of Cancer·2013· 7 cited
[Danish Breast Cancer Cooperative Group].
PubMed·2012· 1 cited
Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial
Journal of Clinical Oncology·2012· 132 cited
Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known <i>HER2</i> and <i>TOP2A</i> status
Molecular Oncology·2011· 18 citedOpen Access
Moderate-Dose Adjuvant Chemotherapy Temporarily Impairs Oral Health-Related Quality of Life
Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology·2011
page 1 of 16Next →

Frequent Co-authors

Maj‐Britt Jensen(9), Bent Ejlertsen(9), Beat Thürlimann(8), Aron Goldhirsch(8), Alan S. Coates(7), Robert Paridaens(7), Richard D. Gelber(7), Marco Colleoni(7), Birgitte Rasmussen(6), L. Mauriac(6), John Forbes(6), István Láng(6), Karen N. Price(6), Armando Santoro(6), Monica Castiglione‐Gertsch(5), Ian Smith(5), D. Thomas(5), Manuela Rabaglio(5), Marie Overgaard(4), M Blichert-Toft(4)